This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Extract of Ginkgo Biloba and Tardive Dyskinesia (EGBTD)

This study has been completed.
Peking University
Information provided by:
Beijing HuiLongGuan Hospital Identifier:
First received: May 2, 2008
Last updated: May 5, 2008
Last verified: May 2008
The purpose of this study is to determine whether Extract of Ginkgo Biloba is effective in the treatment on Tardive dyskinesia

Condition Intervention Phase
Tardive Dyskinesia Schizophrenia Drug: Extract of Ginkgo Biloba (EGb-761 capsules) Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia

Resource links provided by NLM:

Further study details as provided by Beijing HuiLongGuan Hospital:

Primary Outcome Measures:
  • Change in the scores of Abnormal Involuntary Movement Scale (AIMS) [ Time Frame: Baseline, 6th and 12th week ]

Secondary Outcome Measures:
  • Change in PANSS [ Time Frame: Baseline, 6th and 12th week ]
  • Change in Simpson-Angus Rating Scales for EPS [ Time Frame: Baseline, 6th and 12th ]
  • Change in cognitive function [ Time Frame: Baseline and 12th week ]
  • Change in Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale [ Time Frame: Baseline, 6th and 12th week ]

Enrollment: 157
Study Start Date: December 2006
Study Completion Date: August 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
Drug: Extract of Ginkgo Biloba (EGb-761 capsules)
EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
Other Name: YiKangNing
Placebo Comparator: B
Matching placebo treatment
Drug: Placebo
Wheat flour placebo capsule,1 capsule tid, po,12 weeks

Detailed Description:
Tardive dyskinesia(TD) is a common complication of conventional antipsychotic treatment in subjects with schizophrenia. There is no established treatment for TD patients.This disorder remains a significant clinical problem for both patients and physicians for the foreseeable future.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female aged 18 to 60yrs
  • Meeting Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition(DSM-IV) criteria for schizophrenia or schizo-affective disorder
  • Abnormal Involuntary Movement Scale (AIMS) score ≥2.
  • Patients from whom informed, written consent is obtained.
  • Patients who have been on a fixed dose of antipsychotic medication for at least 4 weeks prior to trial entry.

Exclusion Criteria:

  • Significant neurological disorder other than TD
  • Substance abuse
  • Significant other medical illness
  • Psychiatric disorder not stabilised
  • Pregnancy or lactation
  • Take antioxidants(such as Vitamin C)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00672373

Beijing Hui-Long-Guan Hospital
Beijing, China, 100096
Sponsors and Collaborators
Beijing HuiLongGuan Hospital
Peking University
Principal Investigator: Yunlong Tan, Phd Beijing HuiLongGuan Hospital
Study Chair: Dongfeng Zhou, Professor Institute of mental health, Peking University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yun Long Tan, Beijing Hui-Long-Guan Hospital Identifier: NCT00672373     History of Changes
Other Study ID Numbers: EGB-ZWF-01
Study First Received: May 2, 2008
Last Updated: May 5, 2008

Keywords provided by Beijing HuiLongGuan Hospital:
Tardive Dyskinesia
Extract of Gingko Biloba

Additional relevant MeSH terms:
Movement Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms processed this record on September 19, 2017